.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Navigating Advances in NSCLC With EGFR PACC Mutations

Panelists discuss how evolving molecular classification, improved detection methods, and emerging data from novel tyrosine kinase inhibitors like firmonertinib are transforming the treatment of non–small cell lung cancer (NSCLC) with EGFR PACC mutations. They highlight a future where advanced sequencing and innovative therapeutic strategies will enable more precise, effective, and durable management of this complex molecular subset.

Navigating Advances in NSCLC With EGFR PACC Mutations

EP. 1: EGFR PACC Mutations in NSCLC

EP. 2: EGFR PACC Mutation Identification Strategies in NSCLC

EP. 3: Current Treatment Approaches in NSCLC With PACC Mutations

EP. 4: Emerging Data on Firmonertinib for PACC Mutations in NSCLC

EP. 5: Data From the FURTHER Trial in NSCLC With EGFR PACC Mutations

EP. 6: Future Directions for NSCLC With PACC Mutations